ClinicalTrials.gg
CompletedNCT01069939Updated Nov 22, 2012Results posted

Comparative Efficacy & Safety Study of D961H Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With Low-dose Aspirin

A Phase 3 interventional study of Esomeprazole and Placebo in Prevention, sponsored by AstraZeneca. Completed at 46 sites in 3 countries. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2012-11-22.

Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
427
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing esomeprazole in Stomach Ulcer — none open to participants now, none under way, none of them phase 3. Esomeprazole · Stomach Ulcer.

Enrollment
4th of 11
427 · median 400
Started
2010
the only one that year
Phase 3
9 of 11
none open now
Registered
11th of 11
by date
Lead sponsor
10 of 11
AstraZeneca

Among the 11 studies testing esomeprazole in Stomach Ulcer, this one is the 4th largest by enrollment, is the only one that started in 2010, is one of 9 in phase 3, and was the 11th registered.

Stomach Ulcer

116 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.

Browse Stomach Ulcer studies →

Open to participants now

None of the 11 studies testing esomeprazole in Stomach Ulcer is open now. The open studies under Stomach Ulcer, anywhere →

About esomeprazole

Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 10 Stomach Ulcer studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing esomeprazole in Stomach Ulcer as a file.
02

Study summary

To assess the efficacy of D961H 20 mg once daily (q.d.) versus placebo in continuous treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily Low-dose aspirin therapy by evaluating time from randomisation to occurrence of gastric and/or duodenal ulcers.

03

Conditions studied

  • Prevention

Keywords

  • Gastric ulcer
  • Duodenal ulcer
  • Low-dose aspirin
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of written before starting the study-related procedures and examinations
  • Patients who have the history of gastric and/or duodenal ulcer.
  • A diagnosis of a chronic condition (angina pectoris, myocardial infarction and ischemic cerebrovascular disorder, etc., requiring prevention of thrombosis or embolism) which requires taking the prescribed LDA during the study treatment period.

Exclusion criteria

Exclusion Criteria:

  • Having gastric or duodenal ulcer (except for ulcer scar).
  • History of esophageal, gastric or duodenal surgery, except for simple closure of perforation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
427 participants (actual)

Study arms

  • Experimental
    Esomeprazole 20mg

    Esomeprazole 20mg once daily oral

    Drug: Esomeprazole

  • Placebo comparator
    Placebo

    Placebo once daily oral

    Drug: Placebo

Interventions

  • 20mg, capsule, 72 weeks

  • DrugPlacebo

    Placebo, capsule, 72 weeks

06

What researchers measure

Primary outcomes

  1. Time From Randomization to Occurrence of Gastric and/or Duodenal Ulcers up to Data Cut-off Date for Interim Analysis.

    Assessments for occurrence of gastric and/or duodenal ulcers were performed every 12 weeks after randomisation. The numbers of participants with recurrence of gastric and/or duodeal ulcers were analysed every 12 weeks up to 48 weeks.

    Time frame: From randomisation to up to 48 weeks (Maximum follow-up period at the interim analysis)

Secondary outcomes

  1. Change in Degree of Gastric Mucosal Lesion by Modified Lanza Scale From Baseline to Last Measurement up to Week 48

    Modified Lanza scale attributes the degree of gastric mucosal lesion, graded on a 5 point scale (0=No hemorrhage, no erosion, 1=One hemorrhage or one erosions, 2=2-10 hemorrhages or erosions, 3=11-25 hemorrhages or erosions, 4=More than 25 hemorrhages or erosions, or ulcer). Higher scores indicate greater severity of gastric mucosal lesion.

    Time frame: Up to 48 weeks (Baseline to last measurement)

  2. Number of Participants With Reflux Esophagitis Evaluated by the LA Classification up to Week 48.

    Endoscopy was conducted at 12, 24, 36 and 48 weeks after randomisation. At the endoscopy, participants was evaluated whether they have reflux esophagitis or not.

    Time frame: 12, 24, 36 and 48 weeks

  3. Change in the Severity of Epigastric Pain From Baseline to Last Measurement up to Week 48

    The severity of epigastric pain at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into "Improved". If the value was same, categorised into "Unchanged". If the value was worsened, categorise into "Worsened".

    Time frame: Up to 48 weeks (Baseline to last measurement)

  4. Change in the Severity of Heartburn From Baseline to Last Measurement up to Week 48.

    The severity of heartburn at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into "Improved". If the value was same, categorised into "Unchanged". If the value was worsened, categorise into "Worsened".

    Time frame: Up to 48 weeks (Baseline to last measurement)

  5. Change in the Severity of Anorexia From Baseline to Last Measurement up to Week 48

    The severity of anorexia at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into "Improved". If the value was same, categorised into "Unchanged". If the value was worsened, categorise into "Worsened".

    Time frame: Up to 48 weeks (Baseline to last measurement)

  6. Change in the Severity of Abdomen Enlarged Feeling From Baseline to Last Measurement up to Week

    The severity of abdomen enlarged feeling at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into "Improved". If the value was same, categorised into "Unchanged". If the value was worsened, categorise into "Worsened".

    Time frame: Up to 48 weeks (Baseline to last measurement)

  7. Change in the Severity of Nausea and/or Vomiting From Baseline to Last Measurement up to Week 48

    The severity of Nausea and/or Vomiting at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into "Improved". If the value was same, categorised into "Unchanged". If the value was worsened, categorise into "Worsened".

    Time frame: Up to 48 weeks (Baseline to last measurement)

  8. Change in the Severity of Discomfort in the Stomach From Baseline to Last Measurement up to Week 48

    The severity of Discomfort in the stomach at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into "Improved". If the value was same, categorised into "Unchanged". If the value was worsened, categorise into "Worsened".

    Time frame: Up to 48 weeks (Baseline to last measurement)

  9. Number of Participants With Adverse Events

    Participants who had at least adverse events (AE) which occurred after receiving study drug were counted.

    Time frame: Up to 70 weeks at the longest

07

Results

Posted Nov 22, 2012

Participant flow

First participant enrolled on 4 February 2010. On 20 May 2011, the efficacy analysis was completed based on positive results of an interim analysis so that the efficacy data in this report are at the interim analysis. To evaluate the safety, the study was continued. The last participant completed the study on 9 November 2011.

Randomised and Included in the Analyses
Participant flow — Randomised and Included in the Analyses
MilestoneEsomeprazole 20mgPlacebo
Started213214
Completed164137
Not completed4977
Withdrew: Adverse event1722
Withdrew: Withdrawal by subject1512
Withdrew: Lost to follow-up11
Withdrew: Protocol violation01
Withdrew: Lack of efficacy01
Withdrew: Study-specific withdrawal criteria733
Withdrew: Eligibility criteria not fulfilled43
Withdrew: Use of prohibited concomitant drug42
Withdrew: Physician decision02
Withdrew: Removal10
At Data Cut Off Date (26 Feb 2011)
Participant flow — At Data Cut Off Date (26 Feb 2011)
MilestoneEsomeprazole 20mgPlacebo
Started213214
Completed182182
Not completed3132

Outcome measures

PrimaryTime From Randomization to Occurrence of Gastric and/or Duodenal Ulcers up to Data Cut-off Date for Interim Analysis.

Assessments for occurrence of gastric and/or duodenal ulcers were performed every 12 weeks after randomisation. The numbers of participants with recurrence of gastric and/or duodeal ulcers were analysed every 12 weeks up to 48 weeks.

Time frame:
From randomisation to up to 48 weeks (Maximum follow-up period at the interim analysis)
Reported as:
Number · Participants
Time From Randomization to Occurrence of Gastric and/or Duodenal Ulcers up to Data Cut-off Date for Interim Analysis.
ParticipantsEsomeprazole 20mgPlacebo
0 - 12 weeks116
13 - 24 weeks14
25 - 36 weeks02
37 - 48 weeks00
Statistical analysis
  • Esomeprazole 20mg vs Placebo · Log Rank · p = <0.001 (An interim analysis was done so that the significance level was adjusted using the Pocock-like alpha-spending function with Lan-DeMets approach. The adjusted significance level was the two-sided 3.35%.) · Hazard ratio (hr): 0.09 · 96.65% CI 0.02 to 0.41
SecondaryChange in Degree of Gastric Mucosal Lesion by Modified Lanza Scale From Baseline to Last Measurement up to Week 48

Modified Lanza scale attributes the degree of gastric mucosal lesion, graded on a 5 point scale (0=No hemorrhage, no erosion, 1=One hemorrhage or one erosions, 2=2-10 hemorrhages or erosions, 3=11-25 hemorrhages or erosions, 4=More than 25 hemorrhages or erosions, or ulcer). Higher scores indicate greater severity of gastric mucosal lesion.

Time frame:
Up to 48 weeks (Baseline to last measurement)
Reported as:
Mean · Scores on a scale
Change in Degree of Gastric Mucosal Lesion by Modified Lanza Scale From Baseline to Last Measurement up to Week 48
Scores on a scaleEsomeprazole 20mgPlacebo
Change in Degree of Gastric Mucosal Lesion by Modified Lanza Scale From Baseline to Last Measurement up to Week 48-0.4 ± 0.61.3 ± 1.6
SecondaryNumber of Participants With Reflux Esophagitis Evaluated by the LA Classification up to Week 48.

Endoscopy was conducted at 12, 24, 36 and 48 weeks after randomisation. At the endoscopy, participants was evaluated whether they have reflux esophagitis or not.

Time frame:
12, 24, 36 and 48 weeks
Reported as:
Number · Participants
Number of Participants With Reflux Esophagitis Evaluated by the LA Classification up to Week 48.
ParticipantsEsomeprazole 20mgPlacebo
12 weeks09
24 weeks16
36 weeks03
48 weeks00
SecondaryChange in the Severity of Epigastric Pain From Baseline to Last Measurement up to Week 48

The severity of epigastric pain at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into "Improved". If the value was same, categorised into "Unchanged". If the value was worsened, categorise into "Worsened".

Time frame:
Up to 48 weeks (Baseline to last measurement)
Reported as:
Number · Participants
Change in the Severity of Epigastric Pain From Baseline to Last Measurement up to Week 48
ParticipantsEsomeprazole 20mgPlacebo
Improved1116
Unchanged153145
Worsened411
SecondaryChange in the Severity of Heartburn From Baseline to Last Measurement up to Week 48.

The severity of heartburn at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into "Improved". If the value was same, categorised into "Unchanged". If the value was worsened, categorise into "Worsened".

Time frame:
Up to 48 weeks (Baseline to last measurement)
Reported as:
Number · Participants
Change in the Severity of Heartburn From Baseline to Last Measurement up to Week 48.
ParticipantsEsomeprazole 20mgPlacebo
Improved76
Unchanged158154
Worsened312
SecondaryChange in the Severity of Anorexia From Baseline to Last Measurement up to Week 48

The severity of anorexia at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into "Improved". If the value was same, categorised into "Unchanged". If the value was worsened, categorise into "Worsened".

Time frame:
Up to 48 weeks (Baseline to last measurement)
Reported as:
Number · Participants
Change in the Severity of Anorexia From Baseline to Last Measurement up to Week 48
ParticipantsEsomeprazole 20mgPlacebo
Improved910
Unchanged156153
Worsened39
SecondaryChange in the Severity of Abdomen Enlarged Feeling From Baseline to Last Measurement up to Week

The severity of abdomen enlarged feeling at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into "Improved". If the value was same, categorised into "Unchanged". If the value was worsened, categorise into "Worsened".

Time frame:
Up to 48 weeks (Baseline to last measurement)
Reported as:
Number · Participants
Change in the Severity of Abdomen Enlarged Feeling From Baseline to Last Measurement up to Week
ParticipantsEsomeprazole 20mgPlacebo
Improved1824
Unchanged141141
Worsened97
SecondaryChange in the Severity of Nausea and/or Vomiting From Baseline to Last Measurement up to Week 48

The severity of Nausea and/or Vomiting at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into "Improved". If the value was same, categorised into "Unchanged". If the value was worsened, categorise into "Worsened".

Time frame:
Up to 48 weeks (Baseline to last measurement)
Reported as:
Number · Participants
Change in the Severity of Nausea and/or Vomiting From Baseline to Last Measurement up to Week 48
ParticipantsEsomeprazole 20mgPlacebo
Improved85
Unchanged160154
Worsened013
SecondaryChange in the Severity of Discomfort in the Stomach From Baseline to Last Measurement up to Week 48

The severity of Discomfort in the stomach at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into "Improved". If the value was same, categorised into "Unchanged". If the value was worsened, categorise into "Worsened".

Time frame:
Up to 48 weeks (Baseline to last measurement)
Reported as:
Number · Participants
Change in the Severity of Discomfort in the Stomach From Baseline to Last Measurement up to Week 48
ParticipantsEsomeprazole 20mgPlacebo
Improved1315
Unchanged150148
Worsened59
SecondaryNumber of Participants With Adverse Events

Participants who had at least adverse events (AE) which occurred after receiving study drug were counted.

Time frame:
Up to 70 weeks at the longest
Reported as:
Number · Participants
Number of Participants With Adverse Events
ParticipantsEsomeprazole 20mgPlacebo
Adverse event155139
Adverse event (Frequency>=5%)7053
Death00
Serious adverse event other than death1715
Adverse event leading to discontinuation of study1722
Drug-related adverse event3129
Severe adverse event710

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Esomeprazole 20mg—17/214 (7.9%)70/214 (32.7%)
Placebo—15/213 (7%)53/213 (24.9%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventEsomeprazole 20mgPlacebo
Acute Myocardial InfarctionCardiac disorders0/2142/213
Brain Stem HaemorrhageNervous system disorders2/2140/213
DehydrationMetabolism and nutrition disorders0/2141/213
Hip FractureInjury, poisoning and procedural complications0/2141/213
Infective Exacerbation Of Chronic Obstructive Airways DiseaseInfections and infestations0/2141/213
PneumoniaInfections and infestations0/2141/213
GastroenteritisInfections and infestations0/2141/213
Gastritis ErosiveGastrointestinal disorders0/2141/213
Diverticulum Intestinal HaemorrhagicGastrointestinal disorders0/2141/213
Cardiac MyxomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2141/213
Most frequent other events
Most frequent other events
EventEsomeprazole 20mgPlacebo
NasopharyngitisInfections and infestations43/21430/213
ConstipationGastrointestinal disorders12/21411/213
DuodenitisGastrointestinal disorders4/21411/213
Gastric PolypsGastrointestinal disorders11/2141/213

Baseline characteristics

Age, Customized
Age, Customized(Participants)Esomeprazole 20mgPlaceboTotal
<=64years8571156
Between 65 and 74 years8289171
>=75 years4654100
Sex: Female, Male
Sex: Female, Male(Participants)Esomeprazole 20mgPlaceboTotal
Female434689
Male170168338
Region of Enrollment
Region of Enrollment(Participants)Esomeprazole 20mgPlaceboTotal
Taiwan222143
Japan160160320
Korea, Republic of313364
Helicobacter pylori status
Helicobacter pylori status(Participants)Esomeprazole 20mgPlaceboTotal
Positive9393186
Negative117116233
08

Study locations

46 sites
  • Research Site
    Yotsukaidou, Chiba, Japan
  • Research Site
    Kitakyushu-Shi, Fukuoka, Japan
  • Research Site
    Onga-Gun, Fukuoka, Japan
  • Research Site
    Yukuhashi, Fukuoka, Japan
  • Research Site
    Koriyama, Fukushima, Japan
  • Research Site
    Nihonmatsu, Fukushima, Japan
  • Research Site
    Fukuyama, Hiroshima, Japan
  • Research Site
    Kure, Hiroshima, Japan
  • Research Site
    Sapporo, Hokkaido, Japan
  • Research Site
    Amagasaki, Hyogo, Japan
  • Research Site
    Itami, Hyogo, Japan
  • Research Site
    Kobe, Hyogo, Japan
  • Research Site
    Nishinomiya, Hyogo, Japan
  • Research Site
    Higashi-ibaraki,, Ibaraki, Japan
  • Research Site
    Komatsu, Ishikawa, Japan
  • Research Site
    Nomi, Ishikawa, Japan
  • Research Site
    Kawasaki-shi, Kanagawa, Japan
  • Research Site
    Yokohama, Kanagawa, Japan
  • Research Site
    UJI, Kyoto, Japan
  • Research Site
    Sendai, Miyagi, Japan
  • Research Site
    Daito, Osaka, Japan
  • Research Site
    Kishiwada, Osaka, Japan
  • Research Site
    Matsubara, Osaka, Japan
  • Research Site
    Minato, Osaka, Japan
  • Research Site
    Yao, Osaka, Japan
  • Research Site
    Hanyu, Saitama, Japan
  • Research Site
    Shimotsuke, Tochigi, Japan
  • Research Site
    Chuo, Tokyo, Japan
  • Research Site
    Minato, Tokyo, Japan
  • Research Site
    Shinagawa, Tokyo, Japan
  • Research Site
    Shinjuku, Tokyo, Japan
  • Research Site
    Shimonoseki, Yamaguchi, Japan
  • Research Site
    Fukui, Japan
  • Research Site
    Fukuoka, Japan
  • Research Site
    Fukushima, Japan
  • Research Site
    Shizuoka, Japan
  • Research Site
    Gangneung, Gangwon-Do, Korea, Republic of
  • Research Site
    Wonju-si, Gangwon-do, Korea, Republic of
  • Research Site
    Seongnam-si, Gyeonggi-do, Korea, Republic of
  • Research Site
    Busan, Korea, Republic of
  • Research Site
    Seoul, Korea, Republic of
  • Research Site
    Niao-Song-Shiang, Kaohsiung, Taiwan
  • Research Site
    Kweishan Shiang, Taoyuan Hsien, Taiwan
  • Research Site
    Kaohsiung, Taiwan
  • Research Site
    Tainan, Taiwan
  • Research Site
    Taipei, Taiwan
09

References and documents

Publications

  • Sugano K, Choi MG, Lin JT, Goto S, Okada Y, Kinoshita Y, Miwa H, Chiang CE, Chiba T, Hori M, Fukushima Y, Kim HS, Chang CY, Date M; LAVENDER Study Group. Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study. Gut. 2014 Jul;63(7):1061-8. doi: 10.1136/gutjnl-2013-304722. Epub 2013 Dec 10. PubMed 24326741 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2012, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2010
First posted
Feb 17, 2010
Start
Feb 2010
Primary completionActual
Nov 2011
CompletionActual
Nov 2011
Results first posted
Nov 22, 2012
Last update
Nov 22, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01069939
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 17, 2010
Start date
Feb 2010
Primary completion
Nov 2011
Completion
Nov 2011
Results posted
Nov 22, 2012
Last update
Nov 22, 2012

Study contacts

Kentaro Sugano, MD, PhD
principal investigator · Jichi Medical University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esomeprazole

Start the discussion